Proteasome inhibitor bortezomib for the treatment of multiple myeloma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/2404278.pdf
Reference51 articles.
1. Ciechanover A, Orian A, Schwartz AL . Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000; 22: 442–451.
2. Zwickl P, Voges D, Baumeister W . The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1501–1511.
3. Kisselev AF, Goldberg AL . Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001; 8: 739–758.
4. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ . The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9: 6316–6325.
5. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T . The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773–785.
Cited by 104 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma;Cancer Letters;2023-07
2. Subcutaneous injection of a bortezomib-loaded thermosensitive hydrogel for the treatment of multiple myeloma;Chemical Engineering Journal;2023-01
3. Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells;Hematological Oncology;2022-07-14
4. Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis;PharmacoEconomics - Open;2022-06-24
5. Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients;CPT: Pharmacometrics & Systems Pharmacology;2022-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3